Share your experience of delivering myeloma high-risk stratification testing

High-risk myeloma remains one of the most challenging areas of clinical decision-making, with patients experiencing faster disease progression and poorer outcomes driving need for tailored treatment pathways. Yet diagnostic approaches for identifying high-risk disease remain varied across NHS Trusts, and we know colleagues often lack consistent access to the full suite of risk-stratification tools.

If you are a Consultant Haematologist in England, help us understand your experience of delivering risk-stratification testing – complete our survey now.

Laying the groundwork for personalised care

To see progress in this area, it is essential to fully understand how high-risk myeloma is identified and where gaps and inconsistencies exist across NHS Trusts.

Myeloma UK, in partnership with Costello Medical, is working to understand the difficulties facing clinicians when it comes to risk-stratified care. In 2025, we published our initial findings, which highlighted two key issues:

• There is currently a lack of consensus on the criteria for high-risk myeloma.
• There is limited data around the variation in use of currently commissioned risk stratification testing across NHS Trusts in England.

Additional risk-adapted therapy recommendations have been published by Sive et al. (2021)¹ and Kaiser et al. (2024)², although the feasibility of these recommendations is hindered by the lack of routine commissioning in the UK.

Shaping the evidence together

As diagnostic testing receives increasing attention within the NHS, and gene expression profiling is soon to be considered as part of an upcoming evaluation within the NICE HealthTech programme, Myeloma UK are continuing to work with Costello Medical on the second phase of the project. By building a clear, evidence-based picture of the current risk-stratification landscape across NHS Trusts in England, we can better understand current practice, variation between Trusts, and challenges affecting implementation.

We need input from consultant haematologists currently practising in NHS Trusts in England to understand their experiences in delivering risk-stratification testing.

By completing this survey, you will contribute to growing evidence of current practices for identifying and treating high-risk myeloma in the UK. The findings will be used to contribute to national conversations around myeloma risk-stratification and access to personalised treatment, calling for risk-stratification to be part of standard practice across the NHS.

Consultant haematologists who practice in NHS Trusts in England are invited to participate by Friday 17 April 2026.

Share the survey with your colleagues to help us gather more evidence.

Together we will increase the pace of change.